How does repeated annual influenza vaccination impact vaccine efficacy?

Repeated Annual Influenza Vaccination: Effect on Efficacy

Annual influenza vaccination remains strongly recommended because it reduces hospitalization, severe outcomes, and death each season, even if prior-year vaccination may modestly attenuate measured VE in some subgroups and seasons. 1, 2

• Guideline anchor (highest priority for morbidity/mortality/QOL):
  • ACIP 2025–26 and 2024–25: vaccinate every season for all persons ≥6 months; no recommendation to skip or space vaccines due to repeat-dose concerns, as annual vaccination best protects against severe disease across seasons 1, 2.

What repeated vaccination does to effectiveness (practical bottom line)

• Protection vs severe outcomes each year:
  • Children: Annual vaccination confers substantial protection against influenza-associated hospitalization; repeated vaccination showed a modest average reduction in VE vs current-season-only (ΔVE ≈ −13.6%, CI crosses 0), but absolute VE against hospitalization remained clinically meaningful (overall VE ≈ 57%) 3.
• Antigen/subtype nuances:
  • H3N2 shows the most consistent signal of lower VE with repeat vaccination in several analyses; effects are smaller/inconsistent for H1N1 and B, with some seasons showing no decrement or benefits to repeated vaccination 4.
• Immunogenicity patterns (mechanistic/serology):
  • Repeat vaccinees often have higher pre-vaccination titers, smaller day-14/30 fold-rise, yet reach similar titers by 3–6 months, suggesting minimal impact on mid-season protection; updates in vaccine strains mitigate blunting 5, 6. HCW data show blunting when the same strain repeats >3 seasons, improved when strains are updated 7.

Strength of evidence and interpretation

• Highest-quality, most recent clinical outcome data:
  • 2026 multicenter pediatric hospitalization TND: robust, recent, clinically hard endpoint; modest repeat-vaccination decrement but strong absolute protection—supports continuing annual vaccination to reduce hospitalization (morbidity/mortality/QOL) 3.
• Prior high-quality synthesis:
  • 2019 meta-analysis: current-season vaccination always better than none; repeat vs current-only sometimes lower for H3N2/B, but differences vary by season and do not outweigh benefits of being vaccinated in both seasons when considering real-world risk across years 4.
• Observational adult data show possible reduced relative VE in some older adults/seasons, but confounding likely; not grounds to skip vaccination 8. Preprint analyses suggest biases (earlier vaccination, recent/subclinical infection) partly explain observed decrements, especially for H3N2 9.

Actionable recommendations (prioritize severe outcomes)

• Who should vaccinate annually?
  • Everyone ≥6 months without contraindication—do not skip a season due to prior vaccination; annual vaccination protects against hospitalization and death 1, 2.
• How to maximize real-world protection when repeating annually:
  1. Timing:
     • Vaccinate by end of October; vaccinate later if missed—protection persists and late vaccination still reduces severe outcomes. Avoid excessive early vaccination if it meaningfully reduces coverage later, particularly in ≥65s due to waning, but do not delay if it risks missed vaccination 2.
  2. Product selection:
     • Use age-appropriate vaccines; consider high-dose/adjuvanted in older adults per ACIP (unchanged principles) to offset lower H3N2 immunogenicity and age-related blunting 2.
     • Use updated formulations each year; updated antigens help counteract repeat “blunting” 7, 5.
  3. Do not modify schedule to “avoid” repeat effects:
     • Skipping seasons increases susceptibility and worsens morbidity/mortality/QOL risk; guidelines do not advise spacing or alternating years 1, 2.

Key caveats and pitfalls

• Pitfall: Interpreting smaller antibody fold-rise as lower protection.
  • Repeat vaccinees may show smaller early boosts yet achieve similar 3–6 month titers; clinical protection against severe outcomes remains robust 5, 6.
• Pitfall: Overemphasizing H3N2 repeat effects.
  • Any decrement is modest, season-dependent, and outweighed by benefits of being vaccinated, especially for preventing hospitalization/death 3, 4.
• Pitfall: Skipping vaccination to “reset” immunity.
  • Increases risk for severe influenza now, with no guideline support; prioritize current-season protection 1, 2.

Net effect statement for clinicians

• Efficacy impact of repeated annual vaccination is mixed by subtype and season—with the clearest modest attenuation for H3N2—but the most recent and highest-quality clinical evidence and ACIP guidelines concur that annual vaccination meaningfully reduces hospitalizations and severe outcomes each year and should not be deferred or alternated due to prior vaccination history 1, 2, 3.